Teva Pharmaceuticals is a global pharmaceutical company. Its product and service portfolio includes generic medicines, biopharmaceuticals, specialty medicines, OTC products, a distribution business, API and contract manufacturing. The company develops, manufacture,s and sell generic medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Teva offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, high-potency drugs, and cytotoxic substances, in both parenteral and solid dosage forms.
Type | Public | |
Founded | 1901 | |
HQ | Petah Tikva, IL | Map |
Website | tevapharm.com | |
Employee Ratings | ||
Overall Culture | D | More |
USD | |
---|---|
Revenue (Q1, 2022) | 3.7b |
Gross profit (Q1, 2022) | 2.1b |
Net income (Q1, 2022) | (973.0m) |
EBITDA (Q1, 2022) | (225.0m) |
EBIT (Q1, 2022) | (713.0m) |
Market capitalization (26-May-2022) | 3.1t |
Closing stock price (26-May-2022) | 30.8 |
Cash (31-Mar-2022) | 2.2b |
EV | 3.1t |
USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 18.9b | 16.9b | 16.7b | 15.9b |
Cost of goods sold | (8.7b) | (7.6b) | (7.4b) | (7.0b) |
Gross profit | 11.6b | 9.3b | 9.4b | 9.0b |
R&D expense | (1.2b) | (1.0b) | (997.0m) | (967.0m) |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.3b | 4.3b | 4.3b | 4.4b | 3.9b | 4.0b | 4.0b | 3.9b | 3.9b | 3.7b |
Cost of goods sold | (2.0b) | (2.0b) | (2.0b) | (1.9b) | (1.7b) | (1.7b) | (1.7b) | (1.7b) | (1.8b) | (1.6b) |
Gross profit | 2.4b | 2.3b | 2.2b | 2.5b | 2.1b | 2.3b | 2.3b | 2.2b | 2.1b | 2.1b |
R&D expense | (261.0m) | (276.0m) | (241.0m) | (221.0m) | (225.0m) | (258.0m) | (254.0m) | (247.0m) | (222.0m) | (225.0m) |
USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 1.8b | 2.0b | 2.2b | 2.2b |
Accounts Receivable | 5.8b | 5.7b | 4.6b | 4.5b |
Prepaid Expenses | 899.0m | 870.0m | 945.0m | 1.1b |
Inventories | 4.7b | 4.4b | 4.4b | 3.8b |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.0b | 2.2b | 1.2b | 1.8b | 2.4b | 1.8b | 1.7b | 2.4b | 2.0b | 2.2b |
Accounts Receivable | 5.1b | 5.3b | 5.3b | 5.2b | 4.5b | 4.4b | 4.6b | 4.5b | 4.0b | 4.3b |
Prepaid Expenses | 969.0m | 1.1b | 976.0m | 977.0m | 956.0m | 895.0m | 942.0m | 1.0b | 1.1b | 1.1b |
Inventories | 4.8b | 4.9b | 4.6b | 4.3b | 4.4b | 4.5b | 4.4b | 4.4b | 4.2b | 4.0b |
USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | (2.5b) | (1.0b) | (4.1b) | 456.0m |
Depreciation and Amortization | 1.8b | 1.7b | 1.6b | 1.3b |
Inventories | 26.0m | 271.0m | 41.0m | 380.0m |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (97.0m) | (768.0m) | (1.1b) | 25.0m | 78.0m | (4.3b) | 84.0m | 306.0m | 608.0m | (952.0m) |
Depreciation and Amortization | 443.0m | 893.0m | 1.3b | 399.0m | 781.0m | 1.2b | 376.0m | 681.0m | 1.0b | 323.0m |
USD | FY, 2018 |
---|---|
EV/EBITDA | 7.7 x |
EV/EBIT | -25.8 x |
EV/CFO | 18 x |
Revenue/Employee | 443.3k |
Company Name | Date | Deal Size |
---|---|---|
AndaNet | October 03, 2016 | $500 m |
Actavis | August 02, 2016 | $40.5 b |
Rimsa | March 04, 2016 | $2.3 b |
Gecko Health Innovations | September 25, 2015 | |
Auspex Pharmaceuticals | April 04, 2015 | $3.5 b |
Labrys Biologics | June 03, 2014 | $825 m |
NuPathe | January 21, 2014 | $144 m |
MicroDose Therapeutx | June 17, 2013 | $165 m |
Cephalon | October 14, 2011 | $6.8 b |
Barr Pharmaceuticals | July 18, 2008 |
Teva Pharmaceuticals revenue breakdown by business segment: 87.1% from SALE OF GOODS, 8.8% from DISTRIBUTION and 4.2% from Other
Teva Pharmaceuticals revenue breakdown by geographic segment: 30.8% from EUROPE, 49.2% from NORTH AMERICA, 7.2% from OTHER ACTIVITIES and 12.8% from INTERNATIONAL MARKETS
Teva Pharmaceuticals has 3.58k Twitter Followers. The number of followers has increased 0.5% month over month and increased 1.1% quarter over quarter
D
57/100
F
52/100
B-
67/100
D+
58/100
When was Teva Pharmaceuticals founded?
Teva Pharmaceuticals was founded in 1901.
Who are Teva Pharmaceuticals key executives?
Teva Pharmaceuticals's key executives are Richard Daniell, Eric Drapé and Hafrun Fridriksdottir.
How many employees does Teva Pharmaceuticals have?
Teva Pharmaceuticals has 37,100 employees.
What is Teva Pharmaceuticals revenue?
Latest Teva Pharmaceuticals annual revenue is $15.9 b.
What is Teva Pharmaceuticals revenue per employee?
Latest Teva Pharmaceuticals revenue per employee is $428 k.
Who are Teva Pharmaceuticals competitors?
Competitors of Teva Pharmaceuticals include Viatris, WuXi AppTec and Merck.
Where is Teva Pharmaceuticals headquarters?
Teva Pharmaceuticals headquarters is located at 5 Basel St, Petah Tikva.
Where are Teva Pharmaceuticals offices?
Teva Pharmaceuticals has offices in Petah Tikva, Be’er Sheva, Parsippany-Troy Hills, Villa Adelina and in 70 other locations.
How many offices does Teva Pharmaceuticals have?
Teva Pharmaceuticals has 77 offices.
Receive alerts for 300+ data fields across thousands of companies